Bms-907351
Advanced Differentiated Thyroid Gland Carcinoma
ExelixisPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 51/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the Advanced Differentiated Thyroid Gland Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bms-907351 Exelixis | Phase 3 | BB |
Nivolumab Exelixis | Phase 3 | BB |
Atezolizumab Exelixis | Phase 3 | BB |
Enzalutamide Exelixis | Phase 3 | B |
Abiraterone Acetate Exelixis | Phase 3 | B |
View all 14 →
Same molecule, other indications
Bms-907351 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →